Showing 131-140 of 739 results for "".
Winning Combinations
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/winning-combinations/19740/When it comes to helping patients achieve a youthful look, it’s all about the journey, Suneel Chilukuri, MD tells host Joel L. Cohen, MD. You need to continuously update treatment recommendations as patients age and take advantage of combining neuromodulators, fillers, skincare, and energy-based devThe Importance of Continuing Education
https://practicaldermatology.com/series/dermatology-education-foundation/the-importance-of-continuing-education/19993/Continuing education is important for all dermatology PAs, NPs, and physicians. Julie Harper, MD says educational meetings like DERM2021 offer a great opportunity to learn about what's new and how to combine therapies to provide the best care for patients.Laser Options for Scars
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-options-for-scars/18814/Advances in laser technology—particularly fractional lasers—offer an effective option for diminishing the appearance of scars, says Jill Waibel, MD. She offers a review of how she's treating all types of scars and skin types, and discusses how and why keloids have been reclassified as a disease.Advances in Tattoo Removal and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-tattoo-removal-and-more/19756/Eric Bernstein, MD shares insights on the benefits of picosecond domain lasers for everything from rejuvenation to tattoo removal. He discusses his recent experience with the 730nm handpiece and its efficacy on multiple ink colors and all skin types. In addition, he talks about other new technologieDermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cosmetic-surgery-forum-highlights-leo-focuses-on-ad/19703/New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic derThoughts on Superpotent Topical Corticosteroids in Children
https://practicaldermatology.com/topics/psoriasis/thoughts-on-superpotent-topical-corticosteroids-in-children/18684/"I think we've been overtrained that atrophy occurs all the time," says Neil J. Korman, MD. Caution is essential, but super potent topical corticosteroids can be used safely and effectively for pediatric psoriasis patients, he says. Jerry Bagel, MD agrees, in this bonus video from the Clinical ConveGold Mettle: Dr. Michael Gold Talks Multifaceted Practice with Dr. Joel Cohen
https://practicaldermatology.com/topics/practice-management/gold-mettle-dr-michael-gold-talks-multifacted-practice-with-dr-joel-cohen/18868/Dr. Michael Gold's thriving Nashville practice includes a busy medical practice, a medical spa, and a research center. Plus, he's involved in teaching and educational ventures globally. How does he do it all—and stay on schedule? Dr. Joel L. Cohen finds out.- Higher WWI Linked to Increased Mortality Rates in Psoriasis Patientshttps://practicaldermatology.com/news/higher-wwi-linked-increased-mortality-rates-psoriasis-patients/2470869/New research indicates a strong positive correlation between weight-adjusted waist index (WWI) and all-cause mortality in psoriasis patients. Researchers at Wenzhou Medical University in China published “Weight-Adjusted Waist Index, Psoriasis, and All-Cause Mortality: Findings from the NHA
- Eczema Patients at Higher Risk for Comorbidities, Study Findshttps://practicaldermatology.com/news/eczema-patients-higher-risk-comorbidities-study-finds/2468064/Recent analysis of data from the NIH’s All of Us Research Program reveals significant associations between atopic dermatitis (AD) and other health conditions, underscoring the multifaceted burdens faced by AD patients. The All of Us Research Program, which collected health data from over 8
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In